Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial

Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial

Background Patients who completed the originating studies, BREEZE-AD1 (NCT03334396), BREEZE-AD2(NCT03334422), and BREEZE-AD7 (NCT03733301), were eligible for enrollment in the multicenter,phase-3, long-term extension study BREEZE-AD3 (NCT03334435). Methods At week 52, responders and partial responde...

Full description

Bibliographic Details
Main Authors: Jacob P. Thyssen, Thomas Werfel, Sebastien Barbarot, Hamish J.A Hunter, Evangeline Pierce, Luna Sun, Lisa Cirri, Andrew S. Buchanan, Na Lu, Andreas Wollenberg
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Journal of Dermatological Treatment
Subjects:
atopic dermatitis
baricitinib
long-term extension
Online Access:http://dx.doi.org/10.1080/09546634.2023.2190430

Internet

http://dx.doi.org/10.1080/09546634.2023.2190430

Similar Items